TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22325129

Group type: EXPERIMENTAL
Intervention: Focus on Youth in the Caribbean (FOYC) intervention in grade 6 as part of a randomized trial
Number of subjects: 1997

Group type: EXPERIMENTAL
Intervention: Focus on Youth in the Caribbean (FOYC) intervention as part of the regular school curriculum but outside of the trial
Number of subjects: 1997

Group type: COMPARATOR
Intervention: Control condition as part of the trial
Number of subjects: 1997

Group type: COMPARATOR
Intervention: Control condition as part of the school curriculum but outside of the trial
Number of subjects: 1997

Group type: COMPARATOR
Intervention: Naive controls (not enrolled in a school receiving FOYC or the control condition)
Number of subjects: 1997
Study: 19642992

Group type: EXPERIMENTAL
Intervention: Joint reminiscence groups held weekly for twelve consecutive weeks, followed by monthly maintenance sessions for a further seven months
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 400
Study: 17049992

Group type: EXPERIMENTAL
Intervention: Lactitol (oral administration) in addition to standard medical treatment for 3 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard medical treatment (control group) for 3 weeks
Number of subjects: 60
Study: 15896101

Group type: COMPARATOR
Intervention: Darbepoetin alfa
Number of subjects: 300
Study: 15796853

Group type: EXPERIMENTAL
Intervention: Grafting of dermal template (allogeneic acellular dermal matrix) with razor thin autoskin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Grafting of razor thin autoskin only
Number of subjects: 20
Study: 11520089

Group type: EXPERIMENTAL
Intervention: Aboral pouch construction
Number of subjects: 46

Group type: COMPARATOR
Intervention: Simple Roux-en-Y reconstruction
Number of subjects: 46
Study: 9883544

Group type: EXPERIMENTAL
Intervention: Two-stage approach to account for measurement error in surrogate markers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naive method using observed marker values in the Cox model
Number of subjects: 0
Study: 7933268

Group type: EXPERIMENTAL
Intervention: Seeded polytetrafluoroethylene grafts
Number of subjects: 119

Group type: COMPARATOR
Intervention: Autologous vein grafts
Number of subjects: 119
Study: 2893189

Group type: EXPERIMENTAL
Intervention: 10 fish-oil capsules ('MaxEPA') daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: 10 placebo capsules (olive oil) daily
Number of subjects: 28
Study: 31102045

Group type: EXPERIMENTAL
Intervention: Filtek Silorane (silorane-based)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Kalore (methacrylate-based)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Er,Cr:YSGG laser preparation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional diamond bur preparation
Number of subjects: 18
Study: 30253691

Group type: EXPERIMENTAL
Intervention: mWellcare intervention (mHealth system with integrated management of chronic conditions, evidence-based clinical decision support, longitudinal health data, and automated short-messaging service)
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: mWellcare intervention
Number of subjects: 631
Study: 28156007

Group type: EXPERIMENTAL
Intervention: DFT+
Number of subjects: 63

Group type: COMPARATOR
Intervention: DFT-
Number of subjects: 63
Study: 25148765

Group type: EXPERIMENTAL
Intervention: YKP10811 10 mg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: YKP10811 20 mg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: YKP10811 30 mg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 24035957

Group type: EXPERIMENTAL
Intervention: Gabapentin (300 mg) with methadone (40-120 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo with methadone (40-120 mg)
Number of subjects: 60
Study: 21707911

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice-daily for 6 weeks
Number of subjects: 91

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg daily for 6 weeks
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 91

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 91
Study: 19149126

Group type: EXPERIMENTAL
Intervention: Provisc
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Viscoat
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Viscoat + Provisc
Number of subjects: 147
Study: 17135812

Group type: EXPERIMENTAL
Intervention: Resource Use Inventory (RUI) administered at home or in clinic
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Resource Use Inventory (RUI) administered with help of study partners
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Resource Use Inventory (RUI)
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Home-based completion of the RUI
Number of subjects: 644
Study: 12946338

Group type: COMPARATOR
Intervention: Routine 20‐minute period of Electronic Fetal Monitoring (EFM) at the time of admission (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No routine admission EFM (study group)
Number of subjects: 0
Study: 10674594

Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐estradiol (E2) 50 microg/day for 14 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Identical transdermal placebo patches
Number of subjects: 40
Study: 8681562

Group type: EXPERIMENTAL
Intervention: Household cleaning products (proprietary products)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corneosurfametry test
Number of subjects: 0
Study: 1407642

Group type: EXPERIMENTAL
Intervention: Cefotetan (2 gm single preoperative dose)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Cefazolin (3 gm daily for one week post-surgery)
Number of subjects: 86
Study: 2873010

Group type: EXPERIMENTAL
Intervention: 7.5 mg zopiclone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1 mg lormetazepam
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.25 mg triazolam
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1 mg flunitrazepam
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31009765

Group type: EXPERIMENTAL
Intervention: Intranasally administered oxytocin (OT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 46
Study: 28867335

Group type: EXPERIMENTAL
Intervention: Self-monitoring home BP (SMHBP) follow-up with BP target <135/85mmHg
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard follow-up with clinic BP target <140/90mmHg
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 116
Study: 26775631

Group type: EXPERIMENTAL
Intervention: Rectal indomethacin (100 mg dose)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Placebo suppository
Number of subjects: 449
Study: 25139487

Group type: EXPERIMENTAL
Intervention: Topical erythromycin (two applications of 800 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral erythromycin (250 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral erythromycin (1000 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Erythromycin AUC∞
Number of subjects: 16
Study: 22518819

Group type: EXPERIMENTAL
Intervention: Physical-Social Functioning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotional Functioning
Number of subjects: 0
Study: 19083149

Group type: EXPERIMENTAL
Intervention: Antecolic duodenojejunostomy (n = 17)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Vertical retrocolic duodenojejunostomy (n = 18)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups (antecolic and vertical retrocolic)
Number of subjects: 35
Study: 17993095

Group type: EXPERIMENTAL
Intervention: Intravenous propofol infused at a rate of 3 to 4 mg kg(‐1) h(‐1) (Group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No sedation (Group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Theoretical reference values for plasma melatonin levels (Group D)
Number of subjects: 20
Study: 16341745

Group type: EXPERIMENTAL
Intervention: Complex pharmaceutical care intervention by pharmacists
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Final consultation by pharmacists
Number of subjects: 185
Study: 14980069

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (Healthy Volunteers)
Number of subjects: 62
Study: 10444604

Group type: EXPERIMENTAL
Intervention: 0.25LT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.75LT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: LT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1.25LT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1.75LT
Number of subjects: 10

Group type: COMPARATOR
Intervention: C
Number of subjects: 10
Study: 8925656

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (15 mg/kg/day titrated to maximum tolerated dose up to 35 mg/kg/day)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo (titrated similarly to maintain blinding)
Number of subjects: 299
Study: 2035570

Group type: EXPERIMENTAL
Intervention: Continuous electronic fetal heart monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Auscultation at specified intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fetal heart rate deviations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Labor and delivery variables (duration of labor, failure to progress, fetal scalp pH values, presence of meconium)
Number of subjects: 0
Study: 7280386

Group type: EXPERIMENTAL
Intervention: Inspiratory resistive (R) loads at near threshold
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Inspiratory resistive (R) loads at 4-5 times threshold
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Grip responses during R loaded breaths
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Grip responses during E loaded breaths
Number of subjects: 6
Study: 6199481

Group type: COMPARATOR
Intervention: Dacarbazine (DTIC) IV daily for 10 days
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Vinblastine, bleomycin, and cisplatin (VBD)
Number of subjects: 57
Study: 31597207

Group type: EXPERIMENTAL
Intervention: e-cigarette (EC) starter kit
Number of subjects: 886

Group type: COMPARATOR
Intervention: nicotine replacement therapy (NRT)
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: e-cigarettes (EC)
Number of subjects: 886
Study: 29339032

Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Number of subjects: 35
Study: 27266867

Group type: EXPERIMENTAL
Intervention: Fufangdanshen (FFDS) tablets, 3 tablets three times per day for 24 weeks
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo, 3 tablets three times per day for 24 weeks
Number of subjects: 240
Study: 24473459

Group type: EXPERIMENTAL
Intervention: Palaeolithic-type diet (PD)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nordic Nutrition Recommendations (NNR) diet
Number of subjects: 70
Study: 22748456

Group type: EXPERIMENTAL
Intervention: Contusion group (ARDS induced by lung contusion)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (without lung contusion and ARDS)
Number of subjects: 40
Study: 20363879

Group type: EXPERIMENTAL
Intervention: GLP-1 (7-36)-amide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exendin-4 (Ex-4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exendin (Ex)-3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exendin-4(3-39)
Number of subjects: 0
Study: 18684178

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS) guidance
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no EUS guidance)
Number of subjects: 10
Study: 26462765

Group type: EXPERIMENTAL
Intervention: Mucinex 1200 mg (2 x 600 mg extended release tablets)
Number of subjects: 38
Study: 11518588

Group type: EXPERIMENTAL
Intervention: Acoustic analysis of voice parameters (jitter, shimmer, Fo tremor, HNR) during treatment
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group of children without voice pathology
Number of subjects: 46
Study: 9623511

Group type: EXPERIMENTAL
Intervention: Thalidomide treatment for 1 or 2 months
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Thalidomide treatment for 1 month
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Thalidomide treatment for 2 months
Number of subjects: 9
Study: 7512285

Group type: EXPERIMENTAL
Intervention: Short term tube thoracostomy drainage (group 2)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard tube thoracostomy drainage (group 1)
Number of subjects: 25
Study: 3335825

Group type: EXPERIMENTAL
Intervention: 20 micrograms ethinyl estradiol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 micrograms ethinyl estradiol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 micrograms ethinyl estradiol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low doses of estrogen-progestin preparation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 0
Study: 29757661

Group type: EXPERIMENTAL
Intervention: Levothyroxine sodium administered daily either as the whole dose q 24 hr or as half the dose q 12 hr, starting at 0.1 mg/10 lb (0.022 mg/kg) for approximately 6 months
Number of subjects: 92
Study: 26419527

Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (tPA) treatment
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Pretreatment protocol deviations
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Pretreatment deviations
Number of subjects: 557
Study: 25214775

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 22760010

Group type: COMPARATOR
Intervention: On-demand nutritional support (n=26: nutritional intervention if weight loss >5%)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Preventive nutritional support (n=27: regular dietary advice plus energy‐ and protein‐rich evening snack)
Number of subjects: 53
Study: 21428195

Group type: EXPERIMENTAL
Intervention: Hindmilk
Number of subjects: 0

Group type: COMPARATOR
Intervention: 12.5% Sucrose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distilled Water
Number of subjects: 0
Study: 17913605

Group type: EXPERIMENTAL
Intervention: Midazolam and pethidine (Group M: n=27)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Propofol and fentanyl (Group P: n=27)
Number of subjects: 54
Study: 17319111

Group type: EXPERIMENTAL
Intervention: Norepinephrine, Clonidine, L-NMMA (nonselective alpha-adrenoceptor agonists)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methoxamine (selective alpha1-adrenoceptor agonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside (SNP)
Number of subjects: 0
Study: 12095191

Group type: EXPERIMENTAL
Intervention: Imagery condition
Number of subjects: 68

Group type: COMPARATOR
Intervention: No-imagery control condition
Number of subjects: 68
Study: 9796229

Group type: EXPERIMENTAL
Intervention: Immediate ratings with an immediate test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate ratings with a delayed test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delayed ratings with a delayed test
Number of subjects: 0
Study: 7707598

Group type: EXPERIMENTAL
Intervention: School-based prevention program with annual provider training workshops and ongoing consultation
Number of subjects: 3597

Group type: EXPERIMENTAL
Intervention: School-based prevention program with videotaped training and no consultation
Number of subjects: 3597

Group type: COMPARATOR
Intervention: Treatment as usual (controls)
Number of subjects: 3597
Study: 2710801

Group type: EXPERIMENTAL
Intervention: Onion consumption (70 g raw onion daily for 7 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ginger consumption (5 g raw ginger daily for 7 days)
Number of subjects: 12
Study: 1016964

Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Serial echocardiography
Number of subjects: 30
Study: 31600109

Group type: EXPERIMENTAL
Intervention: Autologous PRP gel
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 69
Study: 30083752

Group type: EXPERIMENTAL
Intervention: Electronic health record‐embedded mailed fecal immunochemical test (FIT) outreach program
Number of subjects: 41193

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 41193
Study: 27617680

Group type: EXPERIMENTAL
Intervention: Webcam Lidcombe Program treatment
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard Lidcombe Program treatment
Number of subjects: 49
Study: 24443982

Group type: EXPERIMENTAL
Intervention: Three weeks of plaster cast immobilization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Five weeks of plaster cast immobilization
Number of subjects: 0
Study: 22405570

Group type: EXPERIMENTAL
Intervention: Weekly gemcitabine followed by erlotinib at disease progression (arm A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Erlotinib followed by gemcitabine at progression (arm B)
Number of subjects: 100
Study: 19885979

Group type: EXPERIMENTAL
Intervention: Selection according to baseline characteristics
Number of subjects: 8033

Group type: EXPERIMENTAL
Intervention: Prognostic targeting
Number of subjects: 8033

Group type: EXPERIMENTAL
Intervention: Covariate adjustment
Number of subjects: 8033

Group type: EXPERIMENTAL
Intervention: Selection for targeted treatment effect
Number of subjects: 8033

Group type: EXPERIMENTAL
Intervention: Prognostic targeting for targeted treatment effect
Number of subjects: 8033
Study: 17189085

Group type: EXPERIMENTAL
Intervention: Experimental formula containing 2 x 10(7) colony-forming units of Bifidobacterium longum BL999 and 4 g/L of prebiotic mixture (90% galacto-oligosaccharides and 10% fructo-oligosaccharides)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control formula (not specified)
Number of subjects: 138
Study: 15726029

Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 69

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 69

Group type: COMPARATOR
Intervention: Medication
Number of subjects: 69
Study: 12498548

Group type: EXPERIMENTAL
Intervention: Multi‐compartment conductive plastic tubing liquid cooling/warming garment (LCWG) with inlet water temperatures of 8‐45 degrees C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inlet water temperature of 8 degrees C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inlet water temperature of 45 degrees C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heat transfer calculation standardized per unit tube length and flow rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual thermal profiles design
Number of subjects: 0
Study: 9892571

Group type: EXPERIMENTAL
Intervention: 40 mg intramuscular piroxicam
Number of subjects: 64

Group type: COMPARATOR
Intervention: 75 mg intramuscular diclofenac sodium
Number of subjects: 64
Study: 7539625

Group type: EXPERIMENTAL
Intervention: MACOP-B
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: F-MACHOP
Number of subjects: 18
Study: 2126198

Group type: EXPERIMENTAL
Intervention: Continuous combined oestrogen/progestogen therapy (2 mg of 17 beta‐oestradiol combined with 1 mg of norethisterone acetate orally each day continuously for 5 years)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Continuous combined oestrogen/progestogen therapy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (age-matched untreated women)
Number of subjects: 37
Study: 389150

Group type: EXPERIMENTAL
Intervention: Guanidine hydrochloride (20 to 35 mg/kg per day perorally)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30412909

Group type: EXPERIMENTAL
Intervention: Indigenous Counselling And Nicotine (ICAN) QUIT in Pregnancy intervention including educational resource packages, live interactive webinars, treatment manuals, patient resources, carbon monoxide (CO) meters, and oral Nicotine Replacement Therapy (NRT).
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Indigenous Counselling And Nicotine (ICAN) QUIT in Pregnancy intervention.
Number of subjects: 22
Study: 28263812

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg daily
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1060
Study: 24994768

Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise (PRE) program, 12 weeks, twice a week, using machines with free weights at 50% and 70% of one-repetition maximum (1RM).
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (CG) remained on a waiting list for physical therapy.
Number of subjects: 60
Study: 21584847

Group type: EXPERIMENTAL
Intervention: D-dimer levels measured by VIDAS D-dimer Exclusion (bioMerieux)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: D-dimer levels measured by STA Liatest D-dimer (DiagnosticaStago)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: D-dimer levels measured by HemosIL D-dimer and HemosIL D-dimer HS (Instrumentation Laboratory)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: D-dimer levels measured by Innovance D-dimer (Siemens)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: D-dimer levels measured by AutoDimer (Trinity Biotech)
Number of subjects: 390
Study: 20876669

Group type: EXPERIMENTAL
Intervention: Iron sucrose
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ferric gluconate
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (baseline levels)
Number of subjects: 62
Study: 19118954

Group type: EXPERIMENTAL
Intervention: 10mg oxycodone (OXY)/487 mg acetaminophen (ACET)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 20mg oxycodone (OXY)/975 mg acetaminophen (ACET)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 15 mg hydrocodone (HYD)/487 mg acetaminophen (ACET)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 30mg hydrocodone (HYD)/975 mg acetaminophen (ACET)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: 975 mg acetaminophen (ACET)
Number of subjects: 20
Study: 17971620

Group type: EXPERIMENTAL
Intervention: Community rehabilitation program participants
Number of subjects: 83

Group type: COMPARATOR
Intervention: Non-participants
Number of subjects: 83
Study: 15626251

Group type: EXPERIMENTAL
Intervention: Septoplasty
Number of subjects: 30

Group type: COMPARATOR
Intervention: Preoperative measurements
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Postoperative measurements (4 and 9 months)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Individual case
Number of subjects: 30